🔴 Aspire BioPharma is trading 5.26% down in pre-market — no clear company-specific catalyst identified

Aspire BioPharma is trading 5.26% down at $7.21 after no clear company-specific overnight catalyst was identified.

• The latest major announcement was the August 10 completion of the approximately $30 million Dura Driver Control Systems acquisition, alongside a $22.5 million revolving credit facility.
• Available coverage does not directly connect that news to the August 12 pre-market decline.
• Broader indexes are modestly higher; the decline remains unattributed pending additional filings or announcements.